We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01132690
First Posted: May 28, 2010
Last Update Posted: November 21, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Protalix
Results First Submitted: October 28, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Gaucher Disease
Intervention: Drug: Taliglucerase alfa

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
30 Units/kg Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months
60 Units/kg Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months

Participant Flow:   Overall Study
    30 Units/kg   60 Units/kg
STARTED   6   5 
COMPLETED   6   5 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
30 Units/kg Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months
60 Units/kg Taliglucerase alfa: Taliglucerase alfa for infusion every two weeks for 12 months
Total Total of all reporting groups

Baseline Measures
   30 Units/kg   60 Units/kg   Total 
Overall Participants Analyzed 
[Units: Participants]
 6   5   11 
Age 
[Units: Years]
Mean (Standard Deviation)
 9.5  (4.0)   6.6  (3.1)   8.2  (3.8) 
Age 
[Units: Participants]
     
<=18 years   6   5   11 
Between 18 and 65 years   0   0   0 
>=65 years   0   0   0 
Gender 
[Units: Participants]
     
Female   2   1   3 
Male   4   4   8 
Race (NIH/OMB) 
[Units: Participants]
     
American Indian or Alaska Native   0   0   0 
Asian   0   0   0 
Native Hawaiian or Other Pacific Islander   0   0   0 
Black or African American   0   0   0 
White   6   4   10 
More than one race   0   0   0 
Unknown or Not Reported   0   1   1 
Ethnicity (NIH/OMB) 
[Units: Participants]
     
Hispanic or Latino   3   1   4 
Not Hispanic or Latino   3   4   7 
Unknown or Not Reported   0   0   0 
Region of Enrollment 
[Units: Participants]
     
Paraguay   3   1   4 
South Africa   1   2   3 
Israel   2   2   4 
Religion 
[Units: Participants]
     
Jewish - Ashkenazi   0   2   2 
Jewish - Non-Ashkenazi   0   0   0 
Non Jewish   6   3   9 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Hemoglobin   [ Time Frame: Every 3 months for 12 months ]

2.  Secondary:   Chitotriosidase   [ Time Frame: Every 3 months for 12 months ]

3.  Secondary:   Spleen Volume   [ Time Frame: Baseline and Month 12 ]

4.  Secondary:   Platelet Count   [ Time Frame: Baseline and 12 months ]

5.  Secondary:   Chemokine (C-C Motif) Ligand 18 (CCL18)   [ Time Frame: Every 3 months for 12 months ]

6.  Secondary:   Liver Volume   [ Time Frame: Baseline and Month 12 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Senior VP Development
Organization: Protalix Biotherapeutics
phone: +972-4-902-8100
e-mail: einat@protalix.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Protalix
ClinicalTrials.gov Identifier: NCT01132690     History of Changes
Other Study ID Numbers: PB-06-005
First Submitted: May 26, 2010
First Posted: May 28, 2010
Results First Submitted: October 28, 2014
Results First Posted: November 11, 2014
Last Update Posted: November 21, 2014



To Top